Tanox shares soar in wake of Genentech buyout
13th Nov 2006, 16:15 GMT
Tanox shares gained almost 44% early in the wake of the company's proposed buyout by biotech giant Genentech Shares of Houston-based Tanox jumped $6.11, or 44.8%, to close at $19.75, following the announcement after the markets closed that the company would be acquired by Genentech for $20 a share in cash, or $919 mln.
Tanox shares soar in wake of Genentech buyout related news:
- Genentech to Buy Tanox for $919M and Amgen and Wyeth's ENBREL is the First Biologic to Publish Data Showing Safety and Sustained Efficacy — Financial News USA (OTC: FNWU)
- Solexa's shares soar on $600 million buyout by Illumina — MarketWatch.com - Top Stories – Sponsored by: CyberTrader
- Genentech's Tanox Buyout And Earnings Potential — Bio-Technology News from StratCenter.com
- Isis Pharma's shares soar on cholesterol-drug Phase II data — MarketWatch.com - Top Stories – Sponsored by: CyberTrader
- Drug stocks pare gains; Solexa, Isis shares soar — MarketWatch.com - Top Stories – Sponsored by: CyberTrader
- Islanders close in on buyout bid — BBC News | Scotland | UK Edition
- Buyout funding wait for islanders — BBC News | UK News | Scotland | World Edition
- Potential buyout candidates head lower — MarketWatch.com - Top Stories – Sponsored by: CyberTrader
- Buyout backers secure £2m handout — BBC News | Scotland | UK Edition
- Buyout firms spotted chasing Clear Channel — Marketplace by Bloomberg - International Herald Tribune
Latest news from Bio-Technology News from StratCenter.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Medarex to Receive Milestone Payment from Amgen
- Arqule Early Cancer Study Shows Progress